Dyadic provides phase 1 clinical trial update for its recombinant protein rbd vaccine candidate

Jupiter, fla., july 24, 2023 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today provided an update regarding its phase 1 clinical trial for its dyai-100 covid-19 recombinant protein receptor binding domain (rbd) booster vaccine candidate.
DYAI Ratings Summary
DYAI Quant Ranking